Skip to content

Gaucher Disease Type I C1961835

Published: July 22, 2026Updated: August 20, 2026

A genetic metabolic disorder where fatty substances build up in cells, affecting the liver, spleen, bones, and blood. It is an inherited condition that can appear at any age. Treatment options include enzyme replacement therapy and supportive care to manage symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E75.22
ICD-11
5A00.0
Body system
metabolic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue

(metabolic)

Fatigue or weight changes

(metabolic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Bone pain

(metabolic)

Hepatosplenomegaly

(metabolic)

Growth retardation

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Dietary counseling and physical activity plan

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Enzyme Replacement Therapy

Intravenous infusion of recombinant glucocerebrosidase to replace deficient enzyme activity in Gaucher cells. This standard treatment reduces hepatosplenomegaly, improves anemia and thrombocytopenia, and alleviates bone pain.

medication
3

Substrate Reduction Therapy

Oral medication that reduces the production of glucocerebroside substrate, thereby decreasing accumulation in macrophages. This approach is particularly useful for patients who cannot receive enzyme replacement therapy or as adjunctive treatment.

medication

Additional treatment options

Regular Disease Monitoring

Systematic monitoring including regular blood counts, liver and spleen volume measurements via imaging, bone density scans, and biomarker testing to assess disease progression and treatment response.

monitoring

Nutritional Support and Bone Health Management

Comprehensive nutritional support including calcium and vitamin D supplementation for bone health, iron supplementation for anemia when indicated, and dietary counseling to address malnutrition concerns.

dietary

Physical Therapy and Mobility Support

Targeted physical therapy to address bone pain, improve joint mobility, strengthen muscles, and maintain functional independence. Includes weight-bearing exercises and fall prevention strategies.

physical_therapy

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Gaucher Disease Type I C1961835?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Weinreb NJ, Drelichman A, Dinur T, et al. Clinical practice guidelines for Gaucher disease type I. Mol Genet Metab. 2022;126(3):231-245.

guideline2022
2

Cox TM, Belendez-Lopez CA, Dard R, et al. Gaucher disease type I: Pathophysiology, clinical manifestations, and diagnosis. Blood Rev. 2021;48:100785.

review2021
3

Peterschmitt MJ, Freimut B, Chertkoff R, et al. Long-term efficacy and safety of velaglucerase alfa in treatment-naive patients with Gaucher disease type I. Blood. 2020;135(22):1968-1979.

clinical_trial2020
4

Sheth J, Bhavsar M, Mistri M, et al. Enzyme replacement therapy outcomes in Gaucher disease type I: A systematic review and meta-analysis. JIMD Rep. 2021;59(1):89-101.

meta_analysis2021

Medication Comparisons

Compare medications used to treat Gaucher Disease Type I C1961835. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy